Intellia Therapeutics
Intellia Therapeutics is a biotechnology company focused on the development of therapies using CRISPR/Cas9 gene-editing technology to potentially treat genetic diseases. The company generates revenue through partnerships, collaborations, and the development of proprietary treatments aimed at commercializing innovative gene-editing solutions.
The ten most recent trades of Intellia Therapeutics in all the Ark ETFs ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
---|---|---|---|---|
Jan 21, 2025 | Buy | $225,772 | 0.81% | 0.02% |
Jan 21, 2025 | Buy | $676,578 | 0.81% | 0.01% |
Jan 10, 2025 | Buy | $1,332,853 | 1.46% | 0.02% |
Jan 10, 2025 | Buy | $443,252 | 1.42% | 0.04% |
Jan 08, 2025 | Buy | $898,521 | 0.88% | 0.01% |
Jan 08, 2025 | Buy | $306,671 | 0.88% | 0.03% |
Dec 20, 2024 | Buy | $365,423 | 1.05% | 0.04% |
Dec 20, 2024 | Buy | $2,292,486 | 2.28% | 0.04% |
Dec 18, 2024 | Buy | $307,751 | 0.86% | 0.03% |
Dec 18, 2024 | Buy | $921,283 | 0.90% | 0.01% |